Association between AIRE gene polymorphism and rheumatoid arthritis: a systematic review and meta-analysis of case-control studies by Bérczi, Bálint et al.
1SCIEnTIFIC REPORTS | 7: 14096  | DOI:10.1038/s41598-017-14375-z
www.nature.com/scientificreports
Association between AIRE gene 
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studies
Bálint Bérczi1, Gellért Gerencsér1, Nelli Farkas2, Péter Hegyi3,4,5, Gábor Veres6, Judit Bajor7, 
László Czopf  8, Hussain Alizadeh9, Zoltán Rakonczay10, Éva Vigh11, Bálint Erőss4, Kata 
Szemes7 & Zoltán Gyöngyi1
Autoimmune regulator (AIRE) is a transcription factor that functions as a novel player in immunological 
investigations. In the thymus, it has a pivotal role in the negative selection of naive T-cells during 
central tolerance. Experimental studies have shown that single nucleotide polymorphism (SNP) alters 
transcription of the AIRE gene. SNPs thereby provide a less efficient negative selection, propagate 
higher survival of autoimmune T-cells, and elevate susceptibility to autoimmune diseases. To date, 
only rheumatoid arthritis (RA) has been analysed by epidemiological investigations in relation to 
SNPs in AIRE. In our meta-analysis, we sought to encompass case-control studies and confirm that the 
association between SNP occurrence and RA. After robust searches of Embase, PubMed, Cochrane 
Library, and Web of Science databases, we found 19 articles that included five independent studies. 
Out of 11 polymorphisms, two (rs2075876, rs760426) were common in the five case-control studies. 
Thus, we performed a meta-analysis for rs2075876 (7145 cases and 8579 controls) and rs760426 (6696 
cases and 8164 controls). Our results prove that rs2075876 and rs760426 are significantly associated 
with an increased risk of RA in allelic, dominant, recessive, codominant heterozygous, and codominant 
homozygous genetic models. These findings are primarily based on data from Asian populations.
Rheumatoid arthritis (RA) is a common autoimmune disease associated with chronic synovial inflammation. 
The resultant symmetrical polyarticular arthritis, combined with extra-articular complications, leads to func-
tional impairment. In developed countries, disease prevalence is 0.5–1% of the adult population, and the annual 
incidence has been reported to be 5–50 per 100,0001. Although the aetiology of RA has not been completely 
elucidated, numerous publications agree that autoimmune T-cells may escape from the adaptive immune system 
and, by migrating to the synovium, initiate disease development2–5. RA susceptibility is determined by multiple 
environmental and genetic factors, including several risk alleles. The latest trans-ethnic genome wide association 
study (GWAS), which involved 29,980 RA cases and 73,578 controls, completely screened novel polymorphisms 
in genes contributing to the disease6. One of the associated genes that seems to play a pivotal role in controlling 
autoimmunity is autoimmune regulator (AIRE). The gene is located in the 21q22.3 region, is ∼12.5 kb long, and 
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encodes a 545 amino acid protein of 58 kDa by 14 exonial sequences7–9. The AIRE protein is a transcription factor 
that is indispensable with regards to the negative selection of immature T-cells (thymocytes). Cooperating with 
DNA-binding proteins, AIRE controls the promiscuous expression of peripheral tissue antigens (PTA). Mutations 
in the protein coding gene sequence of AIRE results in the development of autoimmune polyendocrinopathy 
candidiasis-ectodermal dystrophy, an autoimmune deterioration of numerous organs10–12.
To date, increasing numbers of publications have suggested that SNPs in the gene sequence affect AIRE tran-
scription. The SNPs thereby alter the functional activity of AIRE and potentially elevate disease susceptibility7. 
A recent experimental study described two distinct SNPs of AIRE. AIRE−230Y, and AIRE−655G. AIRE−230T 
haplotype transcriptionally modifies AIRE expression and influence negative selection, elevating the risk of 
autoimmunity13. Various SNPs in the AIRE genetic sequence have garnered attention; however, to date, only a 
minority of case-control studies have observed an association between gene polymorphism and susceptibility to 
diseases, including vitiligo7,14, alopecia areata7,15, melanoma7,16, systemic sclerosis7,17 and RA7,18–22. Among the 
latter diseases, only RA has been analysed by multiple case-control studies and, therefore, seems to be optimal to 
analyse positive or negative associations7. Xu et al. have published that AIRE polymorphism was associated with 
the increased risk of RA23. Here, we present a systematic review and first meta-analysis that includes case-control 
studies to verify the association of SNPs rs2075876 and rs760426 in the AIRE gene with RA.
Results
Characteristics of included studies. We identified 19 publications after a thorough search of Embase, 
PubMed, Cochrane Library, and Web of Science databases. After removing duplicates, we reviewed the remain-
ing 11 studies for eligibility and selected five publications for inclusion in our meta-analysis. Our PRISMA flow 
chart of the searching process is shown in Fig. 1. Asian and Caucasian ethnicities were involved. Diagnosis of 
RA was determined according to the American College of Rheumatology classification criteria in 198724. The 
overall mean age of RA patients was 54.1 ± 2.4 years, and the percentage of female cases was 73.34%. Genotyping 
was conducted by microarrays, single base extension methods (SNaPshot), and Taqman SNP Genotyping 
Assays. By further reviewing the five eligible publications, we identified 11 SNPs of the AIRE gene (rs2075876, 
rs760426, rs1800250, rs2776377, rs878081, rs1055311, rs933150, rs1003854, rs2256817, rs374696, rs1078480). 
Only rs2075876 and rs760426 were involved in four or more studies; therefore, we performed meta-analysis for 
rs2075876 (7145 cases and 8579 controls) and rs760426 (6696 cases and 8164 controls). All genotype frequen-
cies of the controls were in Hardy-Weinberg Equilibrium (HWE). Characteristics of the included studies on 
rs2075876 and rs760426 are summarized in Table 1.
Meta-analysis of SNP rs2075876 (G > A). Five studies were identified that investigated the association 
between SNP rs2075876 and RA susceptibility18–22. Most of the publications doubled the individual number to 
account for alleles; thus, to normalize the data, we also calculated with duplicated values (see Supplementary 
Figure 1. PRISMA flow diagram for inclusion and exclusion of studies in the meta-analysis.
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Table S1). GWAS by Terao et al.18 served as three independent case-control studies (denoted with A, B, C). With 
the exception of García-Lozano et al.19, all of the studies described the genotype distribution for GG, AG, AA. 
Therefore, we calculated odds ratios (ORs) for genetic models where there was no available or feasible data in the 
given study (Table 2). Results for each genetic model are shown in Fig. 2. For the allelic model (A vs. G, Fig. 2A) 
the ORs were 1.21 (95% CI 1.09–1.36, P < 0.001), 1.18 (1.07–1.30, P = 0.001), 1.15 (1.06–1.24, P < 0.001), 1.02 
(0.42–2.42, P = 0.964), 1.32 (1.04–1.69, P = 0.021), 1.30 (1.12–1.50, P < 0.00), and 1.41 (1.16–1.70, P < 0.001). 
For the dominant model (AG + AA vs. GG, Fig. 2B) the ORs were 1.18, (95% CI 1.06–1.32, P = 0.002), 1.31 
(1.19–1.45, P < 0.001), 1.18 (1.09–1.27, P < 0.001), 1.41 (1.08–1.84, P = 0.010), 1.55 (1.32–1.82, P < 0.001), and 
1.48 (1.22–1.78, P < 0.001). For the recessive model (AA vs. AG + GG, Fig. 2C) the ORs were 1.53 (95% CI 
1.31–1.79, P < 0.001), 1.09 (0.95–1.26, P = 0.204), 1.25 (1.12–1.39, P < 0.001), 1.52 (1.13–2.05, P = 0.006), 1.25 
(1.05–1.49, P = 0.010), and 1.78 (1.36–2.35, P < 0.001). For the codominant heterozygous model (AG vs. GG, 
see Supplementary Fig. S1), the ORs were 1.08 (0.96–1.21, P = 0.168), 1.32 (1.20–1.47, P < 0.001), 1.13 (1.05–
1.23, P = 0.002), 1.28 (0.97–1.70, P = 0.077), 1.51 (1.28–1.79, P < 0.001), and 1.34 (1.10–1.64, P = 0.003). For the 
codominant homozygous model (AA vs. GG, see Supplementary Fig. S1) the ORs were 1.60 (95% CI 1.35–1.89, 
P < 0.001), 1.27 (1.09–1.48, P = 0.002), 1.34 (1.19–1.51, P < 0.001), 1.78 (1.26–2.52, P = 0.001), 1.62 (1.32–1.99, 
P < 0.001), and 2.09, (1.56–2.81, P < 0.001).
Results of heterogeneity analysis for each genetic model are shown in Supplementary Table S2. For the 
allelic model Ph = 0.439 and I2 = 0%, for the dominant model Ph = 0.011 and I2 = 66.2%, for the recessive model 
Ph = 0.005 and I2 = 69.9%, for the codominant heterozygous model Ph = 0.004 and I2 = 70.5%, and for the codom-
inant homozygous model Ph = 0.012 and I2 = 65.4%. Moderate heterogeneity was found in dominant, recessive, 
codominant heterozygous, and codominant homozygous models.
Only four out of 31 ORs were statistically insignificant, and the ORs revealed that SNP rs2075876 (G > A) 
is associated with an elevated risk of RA. These results therefore suggest a link between AIRE SNP rs2075876 
(G > A) and RA susceptibility.
Meta-analysis of SNP rs760426 (A > G). Four studies investigated the association between SNP 
rs760426 and RA susceptibility18,20–22. Most of the publications doubled the individual number; thus, to normal-
ize the data, we also calculated with duplicated values, as was conducted with rs2075876 SNP (see Supplementary 
Table S1). Again, GWAS by Terao et al.18 served as three independent case-control studies (denoted with A, B, C). 
Year Country Ethnicity
Diagnostic 
criteria Genotyping
Mean age Female % Control 
sourcecase control case control
SNP 
rs2075876(G > A)
Terao C
A 2011 Japan
Asian
American 
College of 
Rheumatology 
for RA (1987)
microarrays 63.0 ± 12.5 52.0 ± 15.8 82.1 60.6 HB
B 2011 microarrays 60.8 ± 11.5 38.1 ± 11.9 84.1 39.6 HB
C 2011 microarrays 61.4 ± 11.5 52.5 ± 15.2 81.4 44.4 HB
García-Lozano JR 2013 Spain Caucasian
American 
College of 
Rheumatology 
for RA (1987)
Taqman SNP 
genotyping 
assay
49.2 ± 14.8 NA 74.3 NA HB
Shao S 2014 China Asian
American 
College of 
Rheumatology 
for RA (1987)
SNaPshot assay 48.7 ± 14.2 47.0 ± 16.3 80.6 37.0 HB
Feng ZJ 2015 China (Han) Asian
American 
College of 
Rheumatology 
for RA (1987)
Taqman SNP 
genotyping 
assay
54.1 ± 11.2 52.4 ± 11.8 53.5 58.5 HB
Li X 2016 China (Shaanxi) Asian
American 
College of 
Rheumatology 
for RA (1987)
Snapshot Assay 43.5 ± 19.2 44.3 ± 17.8 64.3 59.7 HB
SNP rs760426 
(A > G)
Terao C
A 2011
Japan Asian
American 
College of 
Rheumatology 
for RA (1987)
microarrays 63.0 ± 12.5 52.0 ± 15.8 82.1 60.6 HB
B 2011 microarrays 60.8 ± 11.5 38.1 ± 11.9 84.1 39.6 HB
C 2011 microarrays 61.4 ± 11.5 52.5 ± 15.2 81.4 44.4 HB
Shao S 2014 China Asian
American 
College of 
Rheumatology 
for RA (1987)
SNaPshot assay 48.7 ± 14.2 47.0 ± 16.3 80.6 37.0 HB
Feng ZJ 2015 China (Han) Asian
American 
College of 
Rheumatology 
for RA (1987)
Taqman SNP 
genotyping 
assay
54.1 ± 11.2 52.4 ± 11.8 53.5 58.5 HB
Li X 2016 China (Shaanxi) Asian
American 
College of 
Rheumatology 
for RA (1987)
Snapshot Assay 43.5 ± 19.2 44.3 ± 17.8 64.3 59.7 HB
Table 1. Characteristics of the included studies on SNP rs2075876 (G > A) and rs760426 (A > G) (SNP = single 
nucleotide polymorphism; NA = not available; HB = hospital based).
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With the exception of Feng et al.21, all studies described the genotype distribution for AA, GA, GG. We therefore 
calculated ORs for all the genetic models that were not published in the original articles (Table 2). Furthermore, 
we excluded the OR, 95% CI and p-value of Feng et al.21 from the statistical analysis due to the asymmetry of 
the OR. Results for each genetic model are shown in Fig. 3. For the allelic model (G vs. A), Fig. 3A, the ORs 
were 1.23 (95% CI 1.10–1.37, P < 0.001), 1.13 (1.02–1.25, P = 0.011), 1.16 (1.08–1.26, P < 0.001), 1.25 (0.98–1.60, 
P = 0.062), 1.25 (1.04–1.52, P = 0.018). For the dominant model (GG + GA vs. AA, Fig. 3B), the ORs were 1.16 
(1.04–1.29, P = 0.007), 1.19 (1.08–1.31, P < 0.001), 1.18 (1.09–1.27, P < 0.001), 1.19 (0.92–1.55, P = 0.171), and 
OR 1.32 (1.10–1.59, P = 0.003). For the recessive model (GG vs. GA + AA, Fig. 3C) the ORs were 1.66 (95%CI 
Figure 2. The association of SNP rs2075876 (G > A) with RA risk in different genetic models. (A) Allelic model 
(A vs. G). (B) Dominant model (AG + AA vs. GG). (C) Recessive model (AA vs. AG + GG).
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1.43–1.94, P < 0.001), 1.15 (1.00–1.32, P = 0.047), 1.19 (1.07–1.32, P = 0.001), 1.55 (1.16–2.08, P = 0.003), and 
1.36 (1.05–1.77, P = 0.020). For the codominant heterozygous model (GA vs. AA, see Supplementary Fig. S2) 
the ORs were 1.03, (95% CI 0.92–1.16, P = 0.582), 1.17 (1.06–1.30, P = 0.002), 1.15 (1.06–1.25, P = 0.001), 1.04 
(0.79–1.38, P = 0.741), and 1.26 (1.03–1.54, P = 0.020). For the codominant homozygous model (GG vs. AA, see 
Supplementary Fig. S2), the ORs were 1.69 (1.43–2.00, P < 0.001), 1.25 (1.08–1.46, P = 0.003), 1.29 (1.15–1.44, 
P < 0.001), 1.60 (1.15–2.24, P = 0.006), and 1.54 (1.16–2.04, P = 0.003).
Results of heterogeneity analysis for each genetic model are shown in Supplementary Table S2. For the allelic 
model Ph = 0.737, I2 = 0%, for the dominant model Ph = 0.822, I2 = 0%, for the recessive model: Ph = 0.001, 
Figure 3. The association of SNP rs760426 (A > G) with RA risk in different genetic models. (A) Allelic model 
(A vs. G). (B) Dominant model (AG + AA vs. GG). (C) Recessive model (AA vs. AG + GG).
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I2 = 76.7%, for the codominant heterozygous model: Ph = 0.323, I2 = 14.2%, and for the codominant homozy-
gous model Ph = 0.038, I2 = 60.5%. Moderate heterogeneity was found in recessive and codominant homozygous 
models.
Only four out of 26 ORs were statistically insignificant, and the ORs showed that rs760426 (A > G) SNP is 
associated an elevated risk. These results therefore suggest a link between AIRE SNP rs760426 (A > G) and RA 
susceptibility.
Sensitivity analysis. To detect the influence of each case-control study on the whole meta-analysis, we 
performed sensitivity analysis by omitting one individual study. Heterogeneity was not found in SNP rs2075876 
or rs760426 by investigating allelic (Fig. 4), dominant, recessive, codominant heterozygous, and codominant 
homozygous genetic models (see Supplementary Figs S3 and S4).
Publication bias. Bias analysis was performed by generating funnel plots for each polymorphism of the 
allelic (Fig. 5), dominant, recessive, codominant heterozygous, and codominant homozygous genetic models (see 
Supplementary Figs S5 and S6). After analysis, all funnel plots were perfectly symmetric, and no publication bias 
was detected for SNP rs2075876 or rs760426.
Trial sequential analysis. We performed a TSA for the allelic models (Fig. 6) of SNPs rs2075876 (G > A) 
and rs760426 (A > G). Results of allelic models for both polymorphisms showed that the blue line of cumula-
tive z-curve crossed the TSA monitoring boundary and the cumulative sample size was reached. Therefore, we 
observed robust evidence in the association between SNPs rs2075876 (G > A) and rs760426 (A > G) and RA risk. 
These results suggest that no further studies are necessary to confirm the association.
Figure 4. Sensitivity analysis for the allelic models of (A) SNP rs2075876 (G > A) and (B) rs760426 (A > G).
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polymorphism study Genetic model OR 95%CI P
SNP rs2075876 (G > A)
Terao C, 2011
A
Allelic* (A vs. G) 1.21 1.09–1.36 < 0.001
Dominant (AG + AA vs. GG) 1.18 1.06–1.32 0.002
Recessive (AA vs. AG + GG) 1.53 1.31–1.79 < 0.001
Codominant heterozygous (AG vs. GG) 1.08 0.96–1.21 0.168
Codominant homozygous (AA vs. GG) 1.60 1.35–1.89 < 0.001
B
Allelic* (A vs. G) 1.18 1.07–1.30 < 0.001
Dominant (AG + AA vs. GG) 1.31 1.19–1.45 < 0.001
Recessive (AA vs. AG + GG) 1.09 0.95–1.26 0.204
Codominant heterozygous (AG vs. GG) 1.32 1.20–1.47 < 0.001
Codominant homozygous (AA vs. GG) 1.27 1.09–1.48 0.002
C
Allelic* (A vs. G) 1.15 1.06–1.24 < 0.001
Dominant (AG + AA vs. GG) 1.18 1.09–1.27 < 0.001
Recessive (AA vs. AG + GG) 1.25 1.12–1.39 < 0.001
Codominant heterozygous (AG vs. GG) 1.13 1.05–1.23 0.002
Codominant homozygous (AA vs. GG) 1.34 1.19–1.51 < 0.001
García-Lozano JR, 2013
Allelic (A vs. G) 1.02 0.42–2.42 0.964
Dominant (AG + AA vs. GG)
NA
Recessive (AA vs. AG + GG)
Codominant heterozygous (AG vs. GG)
Codominant homozygous (AA vs. GG)
Shao S, 2014
Allelic* (A vs. G) 1.32 1.04–1.69 0.021
Dominant (AG + AA vs. GG) 1.41 1.08–1.84 0.010
Recessive (AA vs. AG + GG) 1.52 1.13–2.05 0.006
Codominant heterozygous (AG vs. GG) 1.28 0.97–1.70 0.077
Codominant homozygous (AA vs. GG) 1.78 1.26–2.52 0.001
Feng ZJ, 2015
Allelic (A vs. G) 1.30 1.12–1.50 < 0.001
Dominant (AG + AA vs. GG) 1.55 1.32–1.82 < 0.001
Recessive (AA vs. AG + GG) 1.25 1.05–1.49 0.010
Codominant heterozygous (AG vs. GG) 1.51 1.28–1.79 < 0.001
Codominant homozygous (AA vs. GG) 1.62 1.32–1.99 < 0.001
Li X, 2016
Allelic* (A vs. G) 1.41 1.16–1.70 < 0.001
Dominant (AG + AA vs. GG) 1.48 1.22–1.78 < 0.001
Recessive (AA vs. AG + GG) 1.78 1.36–2.35 < 0.001
Codominant heterozygous (AG vs. GG) 1.34 1.10–1.64 0.003
Codominant homozygous (AA vs. GG) 2.09 1.56–2.81 < 0.001
SNP rs760426 (A > G)
Terao C, 2011
A
Allelic* (G vs. A) 1.23 1.10–1.37 < 0.001
Dominant (GG + GA vs. AA) 1.16 1.04–1.29 0.007
Recessive* (GG vs. GA + AA) 1.66 1.43–1.94 < 0.001
Codominant heterozygous* (GA vs. AA) 1.03 0.92–1.16 0.582
Codominant homozygous* (GG vs. AA) 1.69 1.43–2.00 < 0.001
B
Allelic* (G vs. A) 1.13 1.02–1.25 0.011
Dominant (GG + GA vs. AA) 1.19 1.08–1.31 < 0.001
Recessive (GG vs. GA + AA) 1.15 1.00–1.32 0.047
Codominant heterozygous (GA vs. AA) 1.17 1.06–1.30 0.002
Codominant homozygous (GG vs. AA) 1.25 1.08–1.46 0.003
C
Allelic* (G vs. A) 1.16 1.08–1.26 < 0.001
Dominant (GG + GA vs. AA) 1.18 1.09–1.27 < 0.001
Recessive (GG vs. GA + AA) 1.19 1.07–1.32 0.001
Codominant heterozygous (GA vs. AA) 1.15 1.06–1.25 0.001
Codominant homozygous (GG vs. AA) 1.29 1.15–1.44 < 0.001
Shao S, 2014
Allelic* (G vs. A) 1.25 0.98–1.60 0.062
Dominant (GG + GA vs. AA) 1.19 0.92–1.55 0.171
Recessive (GG vs. GA + AA) 1.55 1.16–2.08 0.003
Codominant heterozygous (GA vs. AA) 1.04 0.79–1.38 0.741
Codominant homozygous (GG vs. AA) 1.60 1.15–2.24 0.006
Feng ZJ, 2015
Allelic* (G vs. A) 1.87 1.09–2.45 0.074
Dominant (GG + GA vs. AA)
NA
Recessive (GG vs. GA + AA)
Codominant heterozygous (GA vs. AA)
Codominant homozygous (GG vs. AA)
Li X, 2016
Allelic* (G vs. A) 1.25 1.04–1.52 0.018
Dominant (GG + GA vs. AA) 1.32 1.10–1.59 0.003
Recessive (GG vs. GA + AA) 1.36 1.05–1.77 0.020
Codominant heterozygous (GA vs. AA) 1.26 1.03–1.54 0.020
Codominant homozygous (GG vs. AA) 1.54 1.16–2.04 0.003
Table 2. ORs, 95% CIs, and P-values for each genetic model in the association of SNPs rs2075876 (G > A) and 
rs760426 (A > G) with RA risk (NA = not available; OR = odds ratio; CI = confidence interval; * literature data.
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Discussion
RA is a multifactorial disorder where genetic and environmental events equally contribute to disease commence-
ment1,25. The latest GWAS meta-analysis discovered and screened 42 novel RA risk SNPs at a genome level from 
98 candidate biological RA risk genes6. The detected risk genes, including AIRE, are mainly in the category of 
primary immunodeficiency (PID), HIV, and immune dysregulation. With the exception of AIRE, none of the 
other associated proteins have been directly related to central tolerance6.
Self-tolerance involving negative selection, the machinery of which is directed by AIRE, is a central 
immuno-physiological process required to create a normal adaptive immune system. We believe that polymor-
phisms in this indispensable gene lower the protein expression of AIRE, decrease the presentation of self-antigens, 
reduce negative selection, and contribute to the escape and survival of autoimmune T-cells. Reaching the periph-
ery, matured, autoimmune T-cells are a source of autoantibodies and serve as a medium for numerous immune 
disorders, including RA. In support of this belief, Lovewell et al.13 have concluded, through a gene reporter assay, 
that specific haplotypes (AIRE−655G AIRE-230T) can dramatically reduce AIRE transcription. However, with 
in vitro and in vivo experiments, Kont et al.26 have demonstrated that the presentation of PTAs from mTECs is 
quantitatively affected by these reductions in AIRE expression.
An in silico investigation by Terao et al.18, which analysed the expression profile of 210 lymphoblastoid cells in 
the Gene Expression Omnibus (GEO) database, has demonstrated a statistically significant (p < 0.001) correla-
tion between the rs2075876 risk allele (A) and decreased AIRE transcription27. No association was found in GEO 
between rs760426 (G) and AIRE expression. Additionally, García-Lozano et al.19 found statistically significant 
decreases in the expression levels of rs878081 C allele by analysing GEO database. This SNP is located in the Exon 
5 region of AIRE; however, rs2075876 (G > A) is located in Intron 5 and rs760426 (A > G) in Intron 127. The 
latter SNPs may affect the transcription of AIRE by modifying alternative splicing or intron-mediated enhance-
ment28. The reduction in transcription, in turn, provides lower amounts of PTAs ectopically on the major histo-
compatibility complex/human leukocyte antigen of mTECs, which thereby contributes to the failure of negative 
selection in the thymus and increases the survival of autoimmune T-cells. In individuals who carry these SNPs, 
this sequence increases RA susceptibility. By analysing allelic, dominant, recessive, codominant heterozygous, 
and codominant homozygous models, we demonstrated that the SNPs rs2075876 (G > A) and rs760426 (A > G) 
occur more frequently in RA patients than in controls.
There are some limitations in our meta-analysis. We cannot extrapolate the findings of rs2075876 (G > A) 
and rs760426 (A > G) to Caucasians due to the limited study number. Based on García-Lozano et al.19, the results 
are not statistically significant; however, rs878081 C allele seemed to occur more frequently in RA patients. 
Furthermore, considering GWAS of Terao et al.18, the association of AIRE with RA among Caucasians was not 
supported. The number of the included studies also limited our meta-analysis; however, Terao et al.18 provided 
three case-control studies in one publication, which elevated the number of the included epidemiological studies. 
In the future, further European case-control, GWAS, and stratified subgroup analyses (age, smoking) are needed 
in order to better elucidate the association between RA and AIRE polymorphism.
Figure 5. Funnel plots of allelic genetic models of (A) SNP rs2075876 (G > A) and (B) rs760426 (A > G).
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To our knowledge, this is the first time that the association between SNP rs2075876 (G > A), rs760426 (A > G), 
and RA susceptibility was statistically estimated in one meta-analysis. We used multiple haplotype investigations 
for each polymorphism, sensitivity analyses, and TSA to confirm the robustness of association. In conclusion, 
our meta-analysis clearly confirmed with each genetic model that the presence of SNPs rs2075876 (G > A) and 
rs760426 (A > G) is significantly associated with an increased risk for RA.
Methods
Search strategy. We searched for related literature in the PubMed, Embase, Cochrane Library, and Web 
of Science databases in accordance with the recommendations of the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement29. On 16th May 2017 we completed the search. Keywords 
(“autoimmune regulator”; “AIRE”; “polymorphism”; “rheumatoid arthritis”) were thoroughly used by two inde-
pendent investigators. All studies were published from April 2011 to June 2016.
Inclusion and Exclusion criteria. In order for studies to be included, publications had to demonstrate 
that (1) the study focused on the association between SNPs or haplotypes within the AIRE gene and RA suscep-
tibility, (2) the study was case-control-designed, (3) all RA patients met the American College of Rheumatology 
classification and diagnostic criteria, and (4) detailed genotype data and feasible ORs, 95% CIs, and p-values were 
available. Publications were excluded if (1) a previous study was duplicated or (2) the given polymorphism was 
not found in at least four studies. Review articles were also excluded. Inclusion and exclusion criteria were inde-
pendently screened by two investigators.
Statistical analysis. HWE was calculated by the chi-squared test for each study in the control groups. 
Pooled ORs and 95% CIs were calculated to examine the strength of the association between rs2075876 and 
rs760426 polymorphisms and RA. We used the random effect model by DerSimonian and Laird30 because of 
the different ethnicities of those included. Heterogeneity between trials was tested with two methods. First, we 
employed the Cochrane’s Q homogeneity test, which exceeds the upper-tail critical value of chi-square on k–1 
Figure 6. Trial sequential analysis for allelic genetic models of (A) SNP rs2075876 (G > A) and (B) rs760426 
(A > G).
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degrees of freedom, with a p-value of less than 0.10 considered suggestive of significant heterogeneity. Second, we 
used the inconsistency (I2) index. I2 is the proportion of total variation contributed by between-study variability. 
I2 values of 25, 50 and 75% correspond to low, moderate, and high degrees of heterogeneity, respectively, based 
on Cochran’s handbook31. Sensitivity analyses were performed to identify the influence of each study on the 
pooled ORs and 95% CIs. Publication bias was examined by visual inspection of funnel plots where the standard 
error was plotted against the log odds ratio. Meta-analytic calculations were performed with Comprehensive 
MetaAnalysis software Version 3 (Biostat, Inc., Englewood, NJ, USA).
Trial sequential analysis (TSA). Meta-analyses may be biased in type I errors owing to an increased risk of 
random error when sparse data are analysed, combined with reduplicative testing on accumulating data. To avoid 
this problem and to increase the robustness of conclusions, we used trial sequential analysis (TSA)32–34. TSA com-
bines an estimation of the required sample size with an adjusted threshold for statistical significance. The relation-
ship between the cumulative z-curve and the trial sequential monitoring boundary shows the expressiveness of 
the meta-analysis. If the cumulative z-curve crosses the trial sequential monitoring boundary, and the cumulative 
sample size of the meta-analysis reaches the required sample size, firm evidence can be observed. When the 
cumulative z-curve crosses the boundaries, but the sample size does not reach the required information size, a 
sufficient level of evidence for the anticipated intervention effect may have been reached and no further trials are 
needed. If the z-curve does not cross any of the boundaries and the required sample size has not been reached, 
evidence to reach a conclusion is insufficient35. For calculation of the information size, we used a heterogeneity 
adjusted assumption with 10% of relative risk reduction, 5% of overall Type-I-Error, and 10% of Type-II-Error for 
the case of both gene alleles. The adjusted CIs for rs2075876 and rs760426 are 1.13–1.31 and 1.11–1.26, respec-
tively. For calculations we used the Trial Sequential Analysis software tool from Copenhagen Trial Unit, Center 
for Clinical Intervention Research, Denmark (version 0.9 beta, www.ctu.dk/tsa).
All data generated or analysed during this study are included in this published article and its Supplementary 
information file.
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